転移性膵管腺癌（モルフェウス膵癌）患者における複数の免疫療法に基づく治療の併用に関する研究

基本情報

NCT ID: NCT03193190
ステータス: 完了
試験のフェーズ: 第1/第2相
試験タイプ: 介入
目標被験者数: 341
治験依頼者名: Hoffmann-La Roche

概要

A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of patients who have received one line of prior systemic therapy for PDAC. In each cohort, eligible patients will be assigned to one of several treatment arms.

対象疾患

Pancreatic Adenocarcinoma

介入

Nab-Paclitaxel(DRUG)

Gemcitabine(DRUG)

Oxaliplatin(DRUG)

Leucovorin(DRUG)

Fluorouracil(DRUG)

Atezolizumab(DRUG)

Cobimetinib(DRUG)

PEGPH20(DRUG)

BL-8040(DRUG)

Selicrelumab(DRUG)

Bevacizumab(DRUG)

RO6874281(DRUG)

AB928(DRUG)

Tiragolumab(DRUG)

Tocilizumab(DRUG)

依頼者（Sponsor）

中外製薬株式会社(INDUSTRY)

実施施設 (2)

神奈川県立がんセンター

Kanagawa, Japan

国立研究開発法人国立がん研究センター中央病院

Tokyo, Japan